Skip to content
“Data makes you credible; stories make you memorable,” began Amy Niles, Chief Mission Officer of the PAN Foundation, during the Biotechnology Innovation Organization’s (BIO) […]
Show Me the Evidence: Data to Understand and Break Down Patient Access Barriers! Read More »
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
April 17 is World Hemophilia Day, and in commemoration, Bio.News sat down to talk with the National Bleeding Disorders Foundation (NBDF) about the importance
World Hemophilia Day: Raising awareness of the need for a cure Read More »
A trade war will harm American growers and the biotech firms who help them increase productivity, according to the Biotechnology Innovation Organization (BIO). President
Tariffs hurt growers and ag biotech, BIO says Read More »
Maintaining biotechnology superiority is essential to the U.S. economy and national security, and it must be supported with strategic federal funding that leans into
Congressional commission urges support in U.S.-China competition for biotech dominance Read More »
We need policy to improve patient access to drugs and address middlemen who increase drug prices, according to participants in a March 27 healthcare
Summit on health care’s future shines light on PBM abuses Read More »
Appropriate legislation can help innovative biotech firms working on the treatments of the future to build capital, according to congressional testimony from Bill Newell,
Lawmakers should help small biotechs gain capital, BIO Board Member tells House Read More »
U.S. tariffs on imports could increase the cost of biotechnology operations, threatening innovation that helps patients, according to a survey of biotech firms by
BIO survey: Tariffs threaten innovation, access to cures Read More »
Patient perspectives are vital to inform health policy. One agency where such input is particularly crucial is the Centers for Medicare and Medicaid Services
Patient organization engagement of CMS is more important than ever Read More »
The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee
